Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure
Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced the winners of the 2021 Going Digital Awards in Infrastructure. The annual awards program recognizes the extraordinary work of Bentley software users advancing infrastructure design, construction, and operations throughout the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005219/en/
Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure (Photo: Business Wire)
Sixteen independent jury panels selected the 57 finalists from nearly 300 nominations submitted by more than 230 organizations from 45 countries encompassing 19 categories. To see the Going Digital Awards in Infrastructure finalists present their projects, click here.
Bentley Systems showcased 19 Going Digital Awards in Infrastructure winners on December 2 during the 2021 Year in Infrastructure and Going Digital Awards virtual event. On the previous day at the virtual event, 22 Founders’ Honorees were recognized, representing organizations or individuals whose undertakings contribute notably to infrastructure advancement and/or environmental/social development goals.
The winners of the 2021 Going Digital Awards in Infrastructure are:
Bridges
New York State Department of Transportation
East 138th Street over the Major Deegan Expressway
New York City, New York, United States
Buildings and Campuses
Volgogradnefteproekt, LLC
High-tech Multifunctional Medical Complex
Yukki, St. Petersburg, Russia
Digital Cities
Hubei International Logistics Airport Co., Ltd., Shenzhen S.F. Taisen Holdings (Group) Co., Ltd., Airport Construction Engineering Co., Ltd.
Ezhou Huahu Airport Project
Ezhou, Hubei, China
Digital Construction
Clark Construction Group, LLC
SeaTac Airport International Arrivals Facility
Seattle, Washington, United States
Geotechnical Engineering
China Water Resources Beifang Investigation, Design and Research Co. Ltd.
Geological Survey of Water Conservancy and Hydropower Engineering
Tibet, China
Land and Site Development
Liaoning Water Conservancy and Hydropower Survey and Design Research Institute Co., Ltd.
Dongtaizi Reservoir Project
Chifeng, Inner Mongolia, China
Manufacturing
WISDRI Engineering & Research Incorporation Limited
Converter-based Continuous Casting Project of Jinnan Steel Phase II Quwo Base Capacity Reduction and Replacement Project
Quwo, Shanxi, China
Mining and Offshore Engineering
Polyus
Construction of the Blagodatnoye Mill-5
Krasnoyarsk, Krasnoyarsk Krai, Russia
Power Generation
Capital Engineering and Research Incorporation Ltd.
The World’s First 60MW Subcritical Blast Furnace Gas Power Generation Project
Changshu, Jiangsu, China
Project Delivery Information Management
Mott MacDonald Systra JV with Balfour Beatty Vinci
HS2 Phase 1 Main Civil Construction Works
London, United Kingdom
Rail and Transit
Network Rail + Jacobs
Transpennine Route Upgrade
Manchester/Leeds/York, United Kingdom
Reality Modeling
HDR
Diablo Dam Digital Twin Modeling
Whatcom County, Washington, United States
Road and Rail Asset Performance
Collins Engineers, Inc.
Stone Arch Bridge Rehabilitation
Minneapolis, Minnesota, United States
Roads and Highways
PT Hutama Karya (Persero)
Trans Sumatera Toll Road Project Section Serbelawan-Pematangsiantar
Pematangsiantar, Sumatera Utara, Indonesia
Structural Engineering
HDR and the PennFIRST Team
The Pavilion at Penn Medicine
Philadelphia, Pennsylvania, United States
Utilities and Communications
PowerChina Hubei Electric Engineering Co., Ltd.
Suixian and Guangshui 80MWp Ground-based Photovoltaic Power Project of Hubei Energy Group
Guangshui, Hubei, China
Utilities and Industrial Asset Performance
Canadian Energy Company
Asset Data Lifecycle Program
Fort McMurray, Alberta, Canada
Water and Wastewater Treatment Plants
Larson & Toubro Construction
Khatan Group of Villages Water Supply Scheme (Surface Water Treatment), UP, India
Khatan, Uttar Pradesh, India
Water, Wastewater and Stormwater Networks
Companhia Águas de Joinville (CAJ)
Contingency Plan to Ensure Supply in the Event of Drought (Joinville-Santa Catarina)
Joinville, Santa Catarina, Brazil
The students winning the Future Infrastructure Star Challenge are:
Judge’s Choice Winner
Elif Gungormus Deliismail
Mini-Modular-Plant for Digitized Sustainable Campus
Izmir Institute of Technology, Turkey
People’s Choice Winner
Rodman Raul Cordova Rodriguez
Innovative Dam and Hydroelectric Project
Pontifical Catholic University of Rio de Janeiro, Brazil
To view the project descriptions and access the images, visit the Going Digital Awards in Infrastructure webpage. Detailed descriptions of all nominated projects will be published in the print and digital versions of Bentley’s 2021 Infrastructure Yearbook in early 2022. To review the past editions of this publication, access Bentley’s Infrastructure Yearbooks.
Watch the executive sessions and the Going Digital Awards finalists’ presentations from the 2021 Year in Infrastructure and Going Digital Awards virtual event on-demand here.
# #
About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005219/en/
Contact information
Press:
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom